• Oct 26, 2026

  $266.30+0.94%

• Oct 23, 2026

  $263.81-1.42%

  Comparable pharmaceutical companies moved -1.04% on average, with 4 of 6 falling [2]. J&J's decline of 1.42% came alongside that sector weakness. The Financial Times, as relayed by Seeking Alpha, reported that Smith & Nephew had been in talks to merge with a J&J unit and that the talks collapsed [1].

  • 1Seeking Alpha
  • 2Peer group

• Oct 22, 2026

  $267.61+3.81%

  Comparable pharmaceutical companies rose 1.36% on average, with 5 of 6 rising [1]. J&J's gain of 3.81% was larger than the cohort average, so it was only partly shared with the group. The other item that day concerned a different company, Boston Scientific, and does not explain the move.

  • 1Peer group

• Oct 21, 2026

  $257.78-0.61%

• Oct 20, 2026

  $259.36+2.19%

  Johnson & Johnson rose 2.19% on the day, alongside comparable Pharmaceutical Preparations companies, which moved +2.04% on average [1]. Five of the six comparable companies rose and one fell [1]. The move was largely shared with the group.

  • 1Peer group

• Oct 19, 2026

  $253.79-0.69%

  Comparable pharmaceutical companies fell 0.78% on average, with 5 of 6 lower [1]. The stock's 0.69% decline came alongside that sector weakness [1].

  • 1Peer group

• Oct 16, 2026

  $255.56+0.90%

  Seeking Alpha published a story saying Johnson & Johnson was among the winners of EU drug recommendations this month [1]. The other items for the day were opinion pieces, a dividend roundup and a story on an unrelated fund, so they did not report anything that explains the move.

  • 1Seeking Alpha

Closing prices for JNJ. Summaries describe past sessions only and are not advice, a forecast or a recommendation.

Headlines are published by third parties and linked as reported. Amaltash does not endorse or verify them.